Natural occurrence of drug resistance mutations to the HIV ‐1 capsid inhibitor lenacapavir
HIV Medicine · 2025-11 · 26 (11) · 1881-1886
DOI: 10.1111/hiv.70092 ↗Kurz gefasst
Fachartikel in der Zeitschrift HIV Medicine, online erschienen am 07.08.2025. Verfasst von A Weibull Wärnberg und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centrum for Infectious Diseases, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Vetenskapsrådet, Center for Innovative Medicine, Region Stockholm ALF.
Abstract (Originalsprache)
Aims
Lenacapavir (LEN) is a first‐in‐class HIV‐1 capsid inhibitor. We investigated the natural occurrence of LEN drug resistance mutations (DRM) in HIV‐1 sequences from LEN treatment‐naïve individuals.
Methods
We analysed all available HIV‐1 capsid sequences ( n = 21 646) from individuals never exposed to LEN from the Los Alamos National Laboratory database.
Results
LEN DRMs were identified at all LEN DRM‐associated positions, including the highly resistant M66I variant, which was found in 9 sequences across multiple subtypes. In total, 56 sequences (0.26%) contained LEN DRMs. The most prevalent mutation was Q67H ( n = 22), and this mutation was more common in CRF01_AE (17/3053, 0.56%).
Conclusions
All known LEN DRMs can be found in viral populations without drug pressure. This finding may reflect immunological pressure on capsid epitopes containing DRMs. Our findings are of potential clinical relevance for LEN use in both therapeutic and prophylactic applications.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Centrum for Infectious Diseases, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
- Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
- Area of Microbiology of School of Medicine, University of Valladolid, Valladolid, Spain.
- Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden.
Förderung
- Vetenskapsrådet
- Center for Innovative Medicine
- Region Stockholm ALF
- Stiftelsen Läkare mot AIDS Forskningsfond
Zitieren
APA
Weibull Wärnberg, A., Ceña-Diez, R., Sönnerborg, A., & van de Klundert, M. A. A. (2025). Natural occurrence of drug resistance mutations to the HIV ‐1 capsid inhibitor lenacapavir. HIV Medicine, 26(11), 1881-1886. https://doi.org/10.1111/hiv.70092
Vancouver
Weibull Wärnberg A, Ceña-Diez R, Sönnerborg A, van de Klundert MAA. Natural occurrence of drug resistance mutations to the HIV ‐1 capsid inhibitor lenacapavir. HIV Medicine. 2025;26(11):1881-1886. doi:10.1111/hiv.70092
BibTeX
@article{WeibullWrnberg2025,
author = {Weibull Wärnberg, A and Ceña-Diez, R and Sönnerborg, A and van de Klundert, M A A},
title = {Natural occurrence of drug resistance mutations to the HIV ‐1 capsid inhibitor lenacapavir},
journal = {HIV Medicine},
year = {2025},
volume = {26},
number = {11},
pages = {1881--1886},
doi = {10.1111/hiv.70092}
}
EUVIMED